Show simple item record

dc.contributor.authorAccardo, Antonella
dc.contributor.authorAloj, Luigi
dc.contributor.authorAurilio, Michela
dc.contributor.authorMorelli, Giancarlo
dc.contributor.authorTesauro, Diego
dc.date.accessioned2018-12-22T00:31:43Z
dc.date.available2018-12-22T00:31:43Z
dc.date.issued2014
dc.identifier.issn1176-9114
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/287414
dc.description.abstractActive targeting by means of drug encapsulated nanoparticles decorated with targeting bioactive moieties represents the next frontier in drug delivery; it reduces drug side effects and increases the therapeutic index. Peptides, based on their chemical and biological properties, could have a prevalent role to direct drug encapsulated nanoparticles, such as liposomes, micelles, or hard nanoparticles, toward the tumor tissues. A considerable number of molecular targets for peptides are either exclusively expressed or overexpressed on both cancer vasculature and cancer cells. They can be classified into three wide categories: integrins; growth factor receptors (GFRs); and G-protein coupled receptors (GPCRs). Therapeutic agents based on nanovectors decorated with peptides targeting membrane receptors belonging to the GPCR family overexpressed by cancer cells are reviewed in this article. The most studied targeting membrane receptors are considered: somatostatin receptors; cholecystokinin receptors; receptors associated with the Bombesin like peptides family; luteinizing hormone-releasing hormone receptors; and neurotensin receptors. Nanovectors of different sizes and shapes (micelles, liposomes, or hard nanoparticles) loaded with doxorubicin or other cytotoxic drugs and externally functionalized with natural or synthetic peptides are able to target the overexpressed receptors and are described based on their formulation and in vitro and in vivo behaviors.
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.publisherInforma UK Limited
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectPeptides
dc.subjectReceptors, Peptide
dc.subjectAntineoplastic Agents
dc.subjectNanocapsules
dc.subjectMolecular Targeted Therapy
dc.titleReceptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs.
dc.typeArticle
prism.endingPage1557
prism.publicationDate2014
prism.publicationNameInt J Nanomedicine
prism.startingPage1537
prism.volume9
dc.identifier.doi10.17863/CAM.34718
rioxxterms.versionofrecord10.2147/IJN.S53593
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2014-01
dc.contributor.orcidAloj, Luigi [0000-0002-7452-4961]
dc.identifier.eissn1178-2013
rioxxterms.typeJournal Article/Review
cam.issuedOnline2014-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial 4.0 International